BioNTech: From 13 Billion Vaccine Doses to a Cancer Data Crossroads

BioNTech shares climb 7% as Pumitamig cancer data drives optimism, yet analysts caution over reliance on early-stage trial results and slipping timelines.

The sheer scale of BioNTech’s COVID-19 vaccine safety record is difficult to overstate. A fresh analysis of more than 13 billion administered doses confirms a 87% efficacy against infection and 94% protection against fatal outcomes during the primary observation period. The risk of myocarditis remains minimal, clocking in at 12.6 cases per million doses. That mass of real-world evidence provides a technological bedrock as the Mainz-based company pivots toward oncology — a field where it has yet to deliver a single statistically significant, randomized late-stage result.

The current share price reflects that tension. BioNTech shares have climbed to €84.70, a gain of 2.73% in one session and 7.01% over the past week. The rally has brought the stock within striking distance of its 200-day moving average of €85.36, after already crossing above the 50-day line at €80.13. Yet the 52-week high of €105.80 remains over 22% away, and the 30-day annualized volatility sits at a elevated 30.06%, with the RSI reading of 65.5 suggesting the stock is already modestly overbought.

The catalyst for the recent uptick is unmistakable: Pumitamig. This bispecific antibody, developed jointly with Bristol Myers Squibb, is the lead candidate in BioNTech’s effort to transform from a pandemic vaccine maker into a serious oncology player. The company plans to add six more Phase 3 studies in 2026, pushing the total number of registrational trials to 15, with seven late-stage data readouts due throughout the year. None have yet produced final results.

Bullish analysts, notably at Citi, point to the sheer breadth of the pipeline — more than 25 Phase 2 and Phase 3 oncology studies, more than double the count two years ago — and to encouraging early data from a single-arm Phase 2 trial in China, where Pumitamig combined with chemotherapy continued to show antitumor activity and survival signals. If the pivotal global ROSETTA-LUNG-01 study, comparing Pumitamig plus chemo against Atezolizumab plus chemo as first-line treatment for small-cell lung cancer, confirms those signals, the stock could rally toward the analyst consensus of €106.43.

Skeptics argue that the gap between early, single-arm data and robust randomized evidence is precisely where biotech rallies often fray. Cross-trial comparisons can be misleading, especially when a Chinese Phase 2 study with a limited sample is held up against global multi-center registrational trials. BioNTech itself has already demonstrated how timelines can slip: the final readout for Autogene Cevumeran in colorectal cancer was pushed from 2026 to 2027 because events are accumulating more slowly than expected.

On top of that, the oncology ambition coincides with a messy period on the operational side. Co-founders have been departing, and the 2026 outlook came in weaker than the market expected — revenues of €2 billion to €2.3 billion, with the COVID franchise still shrinking and no oncology product sales anticipated this year. That combination dragged the stock sharply lower earlier in the year, and the current price sits 23.92% above the 52-week low of €68.35 — a rally that leaves little buffer if a key readout disappoints. A weak or ambiguous Pumitamig result could send shares quickly back toward the 50-day average or below.

Meanwhile, the legacy business continues to grind. Partner Pfizer is currently gathering clinical data on the latest KP.2 variant vaccine formulation for the 2024/2025 season, with initial results expected in the coming quarters. But those data are unlikely to move the needle. As the secondary article notes, the real lever for the stock is the oncology pipeline — and the market is pricing in a transformation that remains unproven in randomized, late-stage trials.

The next concrete test will come from one of the seven data readouts scheduled for 2026, covering immunomodulators, ADCs, and mRNA immunotherapies. ROSETTA-LUNG-01 is the most watched. Until these registrational studies deliver mature, statistically sound results, the current share price represents hope — not validation.